The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.
Information source: Regional Hospital Holstebro
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Eprosartan (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Regional Hospital Holstebro Official(s) and/or principal investigator(s):
Erling B Pedersen, MD, professor, Study Chair, Affiliation: Department of Medical Research, Holstebro Hospital, Denmark
Summary
We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan
reduces the activity of the sympathetic nervous system in healthy individuals - during
baseline conditions and after activation of the sympathetic nervous system.
Clinical Details
Official title: The Effect of Eprosartan on Vasoactive Hormones and Renal Tubular Function in Healthy Humans.
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind
Primary outcome: Heart rateFractional sodium excretion Plasma levels of noradrenaline
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Both genders.
- Age 18 - 65 years.
- Body mass index less or equal to 30 kg/m2.
- Women must use oral hormonal anticonception, use intrauterine anticonceptive device,
be sterilized/hysterectomized or be postmenopausal.
Exclusion Criteria:
- History or clinical signs of heart, lung, kidney, or endocrine organ disease.
- Abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium,
P-potassium, P-creatinine, P-albumin, P-bilirubin, P-alanine aminotransferase,
P-alkaline phosphatase, P-cholesterol, and B-glucose.
- Abnormal screening of the urine regarding: albumin and glucose
- Malignant disease.
- Known arterial hypertension or measured 24 hour blood pressure above 135 mmHg
systolic or 85 mmHg diastolic.
- Alcohol abuse.
- Smoking.
- Drug use or abuse.
- Known intolerance or allergy to eprosartan or sodium nitroprusside.
- Blood donation within 1 month of the start of the study.
Locations and Contacts
Department of Medical Research, Holstebro Hospital, Holstebro 7500, Denmark
Additional Information
Starting date: November 2006
Last updated: September 13, 2007
|
